2-DEOXY-D-GLUCOSE

Summary

2-Deoxy-D-Glucose (CHEMBL1880349) is a phase-3 clinical-stage small molecule targeting SLC2A1, SLC2A2, and SLC2A3; indicated across 2 conditions including common cold.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Targets: 4 (SLC2A1, SLC2A2, SLC2A3…)
• Indications: 2 conditions
• Clinical trials: 3
• Chemistry: 164.16 Da · C6H12O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1880349
Name	2-DEOXY-D-GLUCOSE
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	40
Molecular formula	C6H12O5
Molecular weight	164.16
InChIKey	PMMURAAUARKVCB-UHFFFAOYSA-N

SMILES: C1C(C(C(OC1O)CO)O)O

IUPAC name: 6-(hydroxymethyl)oxane-2,4,5-triol

Also known as: BA 2758, BA-2758, NSC-15193, SID93576859, SID174006875

Patent coverage: 71 distinct patent families (174 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
SLC2A1	Glucose transporter 1			40.5%	P11166
SLC2A2	Glucose transporter 2			0.2%	P11168
SLC2A3	Glucose transporter 3			0.3%	P11169
SLC2A4	Glucose transporter 4			0%	P14672

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 4 target gene(s): SLC2A1, SLC2A2, SLC2A3, SLC2A4.

Top Reactome pathways

12 total, by targets touching each:

Pathway	Targets	Genes
Cellular hexose transport	4	SLC2A1, SLC2A2, SLC2A3, SLC2A4
Vitamin C (ascorbate) metabolism	2	SLC2A1, SLC2A3
Regulation of insulin secretion	2	SLC2A1, SLC2A2
Translocation of SLC2A4 (GLUT4) to the plasma membrane	1	SLC2A4
Regulation of gene expression in beta cells	1	SLC2A2
Transcriptional regulation of white adipocyte differentiation	1	SLC2A4
Defective SLC2A1 causes GLUT1 deficiency syndrome 1 (GLUT1DS1)	1	SLC2A1
Defective SLC2A2 causes Fanconi-Bickel syndrome (FBS)	1	SLC2A2
Lactose synthesis	1	SLC2A1
Neutrophil degranulation	1	SLC2A3
Intestinal hexose absorption	1	SLC2A2
MECP2 regulates neuronal receptors and channels	1	SLC2A3

Dominant GO biological processes

GO term	Targets
obsolete D-glucose import	4
dehydroascorbic acid transport	4
D-glucose transmembrane transport	4
transmembrane transport	4
transport across blood-brain barrier	3
carbohydrate metabolic process	3
L-ascorbic acid metabolic process	2
D-glucose import across plasma membrane	2
galactose transmembrane transport	2
response to hypoxia	1
central nervous system development	1
female pregnancy	1
long-chain fatty acid import across plasma membrane	1
cerebral cortex development	1
response to insulin	1

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
common cold	2	MONDO:0005709	EFO:0007214

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE2	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05605301	PHASE2	COMPLETED	Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagnosis of Epilepsy
NCT06375772	PHASE2	TERMINATED	A Controlled Human Rhinovirus Infection Study of 2-Deoxy-D-Glucose in Healthy Adults
NCT00096707	PHASE1	COMPLETED	Dose Escalation Trial of 2-Deoxy-D-Glucose (2DG) in Subjects With Advanced Solid Tumors

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

10 molecules share ≥1 primary target. Top 10 by shared-target count:

Molecule	Source	Status	Shared targets
Dapagliflozin	PubChem	Approved	SLC2A1, SLC2A4
EMETINE	ChEMBL	Phase 4 (approved)	SLC2A1
QUERCETIN	ChEMBL + PubChem	Phase 3 (approved)	SLC2A2
GOSSYPOL	ChEMBL	Phase 3	SLC2A1
GENISTEIN	ChEMBL + PubChem	Phase 2 (approved)	SLC2A1
COLFORSIN	ChEMBL	Phase 2	SLC2A1
CYCLOHEXIMIDE	ChEMBL	Phase 2	SLC2A1
anhydrous dextrose	PubChem	Approved	SLC2A1
belumosudil	PubChem	Approved	SLC2A1
Resveratrol	PubChem	Approved	SLC2A3